Published in Cancer Res on May 17, 2013
Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. Elife (2014) 2.48
Metabolic targets for cancer therapy. Nat Rev Drug Discov (2013) 2.32
An Essential Role of the Mitochondrial Electron Transport Chain in Cell Proliferation Is to Enable Aspartate Synthesis. Cell (2015) 2.03
Fatty acid carbon is essential for dNTP synthesis in endothelial cells. Nature (2015) 2.01
Targeting mitochondria metabolism for cancer therapy. Nat Chem Biol (2015) 1.68
Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. J Clin Invest (2015) 1.67
A roadmap for interpreting (13)C metabolite labeling patterns from cells. Curr Opin Biotechnol (2015) 1.44
Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells. Proc Natl Acad Sci U S A (2014) 1.33
Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferation. Mol Cell (2014) 1.26
IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism. Cancer Res (2014) 1.19
Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. J Pathol (2015) 1.12
Endogenous two-photon fluorescence imaging elucidates metabolic changes related to enhanced glycolysis and glutamine consumption in precancerous epithelial tissues. Cancer Res (2014) 1.08
Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality. Physiol Rev (2015) 1.03
Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin Cancer Res (2014) 1.02
Metformin Antagonizes Cancer Cell Proliferation by Suppressing Mitochondrial-Dependent Biosynthesis. PLoS Biol (2015) 1.02
Energy disruptors: rising stars in anticancer therapy? Oncogenesis (2016) 1.02
Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation. Br J Cancer (2014) 0.97
Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. Breast Cancer Res Treat (2014) 0.95
Metformin-induced energy deficiency leads to the inhibition of lipogenesis in prostate cancer cells. Oncotarget (2015) 0.94
Redox control of glutamine utilization in cancer. Cell Death Dis (2014) 0.93
Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation. Sci Rep (2014) 0.93
Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer. World J Urol (2013) 0.92
Metabolic consequences of oncogenic IDH mutations. Pharmacol Ther (2015) 0.90
13C isotope-assisted methods for quantifying glutamine metabolism in cancer cells. Methods Enzymol (2014) 0.88
Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachone. Cancer Metab (2015) 0.88
Coactivator SRC-2-dependent metabolic reprogramming mediates prostate cancer survival and metastasis. J Clin Invest (2015) 0.86
Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype. Oncotarget (2015) 0.84
Environment Dictates Dependence on Mitochondrial Complex I for NAD+ and Aspartate Production and Determines Cancer Cell Sensitivity to Metformin. Cell Metab (2016) 0.83
Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer. J Biol Chem (2014) 0.82
Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1). Clin Cancer Res (2013) 0.82
In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors. BMC Cancer (2015) 0.79
Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy. J Clin Oncol (2016) 0.79
Glycolytic switch in response to betulinic acid in non-cancer cells. PLoS One (2014) 0.79
Metformin suppressed the proliferation of LoVo cells and induced a time-dependent metabolic and transcriptional alteration. Sci Rep (2015) 0.78
Amino acid management in cancer. Semin Cell Dev Biol (2015) 0.78
Metabolic requirements for cancer cell proliferation. Cancer Metab (2016) 0.77
Mitochondrial mutations and metabolic adaptation in pancreatic cancer. Cancer Metab (2017) 0.77
The combination of 13N-ammonia and 18F-FDG whole-body PET/CT on the same day for diagnosis of advanced prostate cancer. Nucl Med Commun (2016) 0.76
Troglitazone suppresses glutamine metabolism through a PPAR-independent mechanism. Biol Chem (2015) 0.76
Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer. Cell Rep (2017) 0.75
PHD2 Targeting Overcomes Breast Cancer Cell Death upon Glucose Starvation in a PP2A/B55α-Mediated Manner. Cell Rep (2017) 0.75
Metabolic engineering of lactate dehydrogenase rescues mice from acidosis. Sci Rep (2014) 0.75
Potential role for metformin in urologic oncology. Investig Clin Urol (2016) 0.75
Medium Renewal Blocks Anti-Proliferative Effects of Metformin in Cultured MDA-MB-231 Breast Cancer Cells. PLoS One (2016) 0.75
Glutamine Metabolism in Cancer: Understanding the Heterogeneity. Trends Cancer (2017) 0.75
Metabolic heterogeneity signature of primary treatment-naïve prostate cancer. Oncotarget (2017) 0.75
PET Tracers Beyond FDG in Prostate Cancer. Semin Nucl Med (2016) 0.75
LKB1 promotes metabolic flexibility in response to energy stress. Metab Eng (2016) 0.75
LMP1-mediated glycolysis induces myeloid-derived suppressor cell expansion in nasopharyngeal carcinoma. PLoS Pathog (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab (2008) 18.87
Regulation of cancer cell metabolism. Nat Rev Cancer (2011) 15.44
Cancer cell metabolism: Warburg and beyond. Cell (2008) 11.80
Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell (2008) 11.18
A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell (2007) 9.20
Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature (2011) 7.94
Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev (2008) 7.87
Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol (2011) 7.07
Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature (2011) 6.57
Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci (2010) 6.30
New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care (2009) 6.17
Targeting metabolic transformation for cancer therapy. Nat Rev Cancer (2010) 5.90
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene (2008) 5.85
Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene (2009) 5.81
Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov (2011) 5.79
Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell (2010) 5.02
Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A (2010) 4.97
Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab (2012) 4.80
LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell (2013) 4.58
Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) (2012) 4.04
Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med (2010) 3.99
Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care (2010) 3.68
Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol (2012) 3.40
Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer (2008) 3.39
Elementary metabolite units (EMU): a novel framework for modeling isotopic distributions. Metab Eng (2006) 3.23
Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care (2012) 3.11
Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov (2012) 3.02
Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res (2011) 2.93
Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care (2009) 2.90
Determination of confidence intervals of metabolic fluxes estimated from stable isotope measurements. Metab Eng (2006) 2.79
Quantifying reductive carboxylation flux of glutamine to lipid in a brown adipocyte cell line. J Biol Chem (2008) 2.76
The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell (2013) 2.70
Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res (2010) 2.60
Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control (2009) 2.49
An elementary metabolite unit (EMU) based method of isotopically nonstationary flux analysis. Biotechnol Bioeng (2008) 1.98
RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res (2003) 1.97
Small molecule activation of PKM2 in cancer cells induces serine auxotrophy. Chem Biol (2012) 1.96
Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Res (2007) 1.81
Determination of metabolic flux ratios from 13C-experiments and gas chromatography-mass spectrometry data: protocol and principles. Methods Mol Biol (2007) 1.76
Isotopomer spectral analysis of triglyceride fatty acid synthesis in 3T3-L1 cells. Am J Physiol (1992) 1.49
Cancer metabolism: is glutamine sweeter than glucose? Cancer Cell (2010) 1.41
Effect of anaplerotic fluxes and amino acid availability on hepatic lipoapoptosis. J Biol Chem (2009) 1.15
Effects of hypoxia and HIFs on cancer metabolism. Int J Hematol (2012) 1.13
Carbon source and myc expression influence the antiproliferative actions of metformin. Cancer Res (2012) 1.07
Citrate transport and metabolism in mammalian cells: prostate epithelial cells and prostate cancer. Bioessays (2009) 0.98
Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 49.82
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
AKT/PKB signaling: navigating downstream. Cell (2007) 31.26
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2009) 19.65
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature (2008) 18.20
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet (2006) 17.19
Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res (2003) 15.74
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol (2009) 13.89
The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science (2005) 12.35
The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A (2004) 12.30
Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature (2006) 12.13
Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell (2002) 11.65
Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci U S A (2004) 10.78
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest (2008) 10.74
Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature (2004) 10.32
Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature (2008) 9.77
ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev (2004) 9.54
The Sir2 family of protein deacetylases. Annu Rev Biochem (2004) 9.28
Mammalian SIRT1 represses forkhead transcription factors. Cell (2004) 8.89
Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell (2006) 8.48
Calorie restriction extends Saccharomyces cerevisiae lifespan by increasing respiration. Nature (2002) 8.45
Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev (2002) 8.31
Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol (2003) 8.25
Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab (2008) 7.97
Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature (2011) 7.94
Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene (2004) 7.92
Bidirectional transport of amino acids regulates mTOR and autophagy. Cell (2009) 7.88
The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell (2004) 7.77
Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell (2010) 7.61
Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell (2003) 7.42
Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell (2008) 7.37
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell (2012) 7.36
Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol (2011) 7.07
The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. Cell (2003) 7.04
Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates. Science (2003) 6.97
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet (2011) 6.89
Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A (2008) 6.84
SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell (2006) 6.79
mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell (2005) 6.71
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature (2013) 6.53
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A (2005) 6.35
Calorie restriction, SIRT1 and metabolism: understanding longevity. Nat Rev Mol Cell Biol (2005) 6.34
A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med (2013) 6.09
Molecular interpretation of ERK signal duration by immediate early gene products. Nat Cell Biol (2002) 6.05
Two neurons mediate diet-restriction-induced longevity in C. elegans. Nature (2007) 5.94
Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science (2011) 5.73
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest (2006) 5.73
Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science (2011) 5.72
Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell Metab (2005) 5.61
A PtdInsP(3)- and Rho GTPase-mediated positive feedback loop regulates neutrophil polarity. Nat Cell Biol (2002) 5.58
Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal (2009) 5.57
Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biol (2005) 5.54
mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol (2004) 5.46
Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science (2010) 5.44
SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell (2007) 5.30
Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci U S A (2004) 5.16
A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet (2006) 5.10
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res (2005) 5.07
Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A (2005) 5.05
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA (2009) 5.05
A rapid method for determining protein kinase phosphorylation specificity. Nat Methods (2004) 5.04
SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol Cell (2007) 5.01
Isoprenoid pathway optimization for Taxol precursor overproduction in Escherichia coli. Science (2010) 4.96
Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A (2002) 4.93
The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol (2008) 4.92
Increase in activity during calorie restriction requires Sirt1. Science (2005) 4.90
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov (2011) 4.78
Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature (2013) 4.71
Calorie restriction extends yeast life span by lowering the level of NADH. Genes Dev (2004) 4.51
RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem (2007) 4.45
A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange. Nature (2008) 4.43
Protein sequences from mastodon and Tyrannosaurus rex revealed by mass spectrometry. Science (2007) 4.41
Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell (2009) 4.30
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst (2005) 4.19
A role for SIR-2.1 regulation of ER stress response genes in determining C. elegans life span. Dev Cell (2005) 4.16
Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. Mol Cell (2010) 4.07
Tuning genetic control through promoter engineering. Proc Natl Acad Sci U S A (2005) 4.07
Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2006) 4.02
TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr Biol (2003) 4.01
MAPK signal specificity: the right place at the right time. Trends Biochem Sci (2006) 3.96